Vonoprazan CAS 881681-00-1

Product Description:

Product Name: Vonoprazan CAS NO: 881681-00-1

Synonyms:

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine;

1H-Pyrrole-3-methanamine,5-(2-fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl);

Voronazan interfluoroisomer;

Chemical & Physical Properties:

Appearance: Solid

Assay :≥99.0%

Density: 1.31±0.1 g/cm3(Predicted)

Boiling Point: 530.3±60.0 ℃(Predicted)

Vapour Pressure: 0.0±1.4 mmHg at 25℃

Index of Refraction: 1.622

Vanoprazan fumarate is a new oral gastric acidity drug developed by Takeda Pharmaceutical and Otsuka Pharmaceuticals. It is used to treat duodenal ulcers, gastric ulcers, reflux esophagitis, gastric ulcers or recurrent duodenal ulcers caused by low dosages of Aspirin, and Helicobacter pylori. It can also supplement treatment of gastric ulcers, duodenal ulcers, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, early gastric cancer, and Helicobacter pylori infection gastritis.

Compared to traditional irreversible proton pump inhibitors (omeprazole, esomeprazole, etc.), Takecab has the following advantages:

1. Rapid effects, having the most drastic acid-suppressing effects on the first day of ingestion.

2. Oral intake, efficacy unaffected by gastric acid, does not require enteric administration.

Alleviated nighttime acid reflux.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.